Human disease
autoimmune hemolytic anemia
Mondo defines it as: “Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in hemolytic anemia.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 432 | Haemolytic anaemia, autoimmune | OMIA's OMIM numbers | 2 | Human disease |
37.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Sutimlimab | None of these genes | Approved |
| Cyclosporine | None of these genes | Phase 3 |
| Fostamatinib | None of these genes | Phase 3 |
| Ianalumab | None of these genes | Phase 3 |
| Mycophenolate Mofetil | None of these genes | Phase 3 |
| Obexelimab | None of these genes | Phase 3 |
| Parsaclisib | None of these genes | Phase 3 |
| Prednisolone | None of these genes | Phase 3 |
| Rilzabrutinib | None of these genes | Phase 3 |
| Rituximab | None of these genes | Phase 3 |
| Alemtuzumab | None of these genes | Phase 2/3 |
| Nipocalimab | None of these genes | Phase 2/3 |
| Acalabrutinib | None of these genes | Phase 2 |
| Anx-005 | None of these genes | Phase 2 |
| Batoclimab | None of these genes | Phase 2 |
| Bortezomib | None of these genes | Phase 2 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 2 |
| Dexamethasone | None of these genes | Phase 2 |
| Doxorubicin | None of these genes | Phase 2 |
| Fludarabine | None of these genes | Phase 2 |
| Fludarabine Phosphate | None of these genes | Phase 2 |
| Ibrutinib | None of these genes | Phase 2 |
| Ixazomib | None of these genes | Phase 2 |
| Orelabrutinib | None of these genes | Phase 2 |
| Orilanolimab | None of these genes | Phase 2 |
| Pegcetacoplan | None of these genes | Phase 2 |
| Prednisone | None of these genes | Phase 2 |
| Telitacicept | None of these genes | Phase 2 |
| Vincristine | None of these genes | Phase 2 |
| Zanubrutinib | None of these genes | Phase 2 |
| Zetomipzomib | None of these genes | Phase 2 |
| Zolacabtagene Autoleucel | None of these genes | Phase 2 |
| Povetacicept | None of these genes | Phase 1/2 |
| Daratumumab | None of these genes | Phase 1 |
| Hyaluronidase | None of these genes | Phase 1 |
| Inaticabtagene Autoleucel | None of these genes | Phase 1 |
| Linperlisib | None of these genes | Phase 1 |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Unknown |
| Darbepoetin Alfa | None of these genes | Unknown |
| Epoetin Alfa | None of these genes | Unknown |
| Epoetin Beta | None of these genes | Unknown |
| Filgrastim | None of these genes | Unknown |
| Hydrocortisone | None of these genes | Unknown |
| Iptacopan | None of these genes | Unknown |
| Lenograstim | None of these genes | Unknown |
| Luspatercept | None of these genes | Unknown |
| Methylprednisolone | None of these genes | Unknown |
| Pegfilgrastim | None of these genes | Unknown |
| Sirolimus | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.